"Gout" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Metabolic disorder characterized by recurrent acute arthritis, hyperuricemia and deposition of sodium urate in and around the joints, sometimes with formation of URIC ACID calculi.
| Descriptor ID |
D006073
|
| MeSH Number(s) |
C05.550.114.423 C05.550.354.500 C05.799.414 C16.320.565.798.368 C18.452.648.798.368
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Gout".
Below are MeSH descriptors whose meaning is more specific than "Gout".
This graph shows the total number of publications written about "Gout" by people in this website by year, and whether "Gout" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2003 | 0 | 1 | 1 |
| 2004 | 1 | 0 | 1 |
| 2005 | 4 | 0 | 4 |
| 2006 | 1 | 0 | 1 |
| 2007 | 2 | 0 | 2 |
| 2008 | 4 | 0 | 4 |
| 2009 | 4 | 0 | 4 |
| 2010 | 2 | 1 | 3 |
| 2011 | 6 | 0 | 6 |
| 2012 | 3 | 0 | 3 |
| 2013 | 2 | 0 | 2 |
| 2014 | 4 | 0 | 4 |
| 2015 | 1 | 2 | 3 |
| 2016 | 2 | 0 | 2 |
| 2017 | 1 | 2 | 3 |
| 2018 | 2 | 0 | 2 |
| 2019 | 1 | 0 | 1 |
| 2021 | 1 | 0 | 1 |
| 2022 | 2 | 0 | 2 |
| 2023 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Gout" by people in Profiles.
-
Purine-ifying uric acid by gut microbes. Cell Chem Biol. 2023 07 20; 30(7):706-708.
-
Orthopaedic Management of Gout. J Am Acad Orthop Surg Glob Res Rev. 2022 11 01; 6(11).
-
Evaluation of the Relationship Between Serum Urate Levels, Clinical Manifestations of Gout, and Death From Cardiovascular Causes in Patients Receiving Febuxostat or Allopurinol in an Outcomes Trial. Arthritis Rheumatol. 2022 09; 74(9):1593-1601.
-
Management of Gout. JAMA. 2021 Dec 28; 326(24):2519-2520.
-
Efficacy and Safety of Febuxostat Extended and Immediate Release in Patients With Gout and Renal Impairment: A Phase III Placebo-Controlled Study. Arthritis Rheumatol. 2019 01; 71(1):143-153.
-
Efficacy and safety of febuxostat extended release and immediate release in patients with gout and moderate renal impairment: phase II placebo-controlled study. Arthritis Res Ther. 2018 05 30; 20(1):99.
-
Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout. N Engl J Med. 2018 Mar 29; 378(13):1200-1210.
-
Cervicomedullary compression as the main manifestation of wild-type transthyretin amyloidosis. Amyloid. 2017 06; 24(2):133-134.
-
Toxic Epidermal Necrolysis with Gastrointestinal Involvement: A Case Report and Review of the Literature. J Burn Care Res. 2017 Jan/Feb; 38(1):e450-e455.
-
Lesinurad Combined With Allopurinol: A Randomized, Double-Blind, Placebo-Controlled Study in Gout Patients With an Inadequate Response to Standard-of-Care Allopurinol (a US-Based Study). Arthritis Rheumatol. 2017 01; 69(1):203-212.